Andere Sprachen Oculis Holding AG

Aktien

OCS

CH1242303498

OCS

Schlusskurs Nasdaq Andere Börsenplätze 00:00:00 28.05.2024			% 5 Tage	% 1. Jan.
11,9 ^USD	+0,42 %		0,00 %	+5,97 %

08.05.	Oculis Holding AG meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
24.04.	OCULIS HOLDING AG : HC Wainwright bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Oculis Holding - Increase in share capital	21.05.
Oculis updates share capital for its existing at-the-market offering program	17.05.
Oculis : Entry into Sales Agreement with Leerink Partners, LLC - Form 6-K	08.05.
Oculis : Form 6-K	08.05.
Oculis Reports Q1 2024 Financial Results and Provides Company Updates	08.05.
Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis	08.05.
Oculis Publishes Invitation to the Annual General Meeting	07.05.
Oculis to Present at Bank of America Global Healthcare Conference	06.05.
Oculis Publishes Invitation to the Annual General Meeting	29.04.
Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index	24.04.
Oculis Completes $59 Million Direct Offering of Shares	22.04.
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market	22.04.
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market	11.04.
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development	10.04.
Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development	10.04.
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting	08.04.
Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery	08.04.
Oculis to Participate at Upcoming April Investor Conferences	04.04.
Oculis Holding Files $300 Million Mixed-Securities Shelf Registration	01.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Oculis Holding AG

Aktien

OCS

CH1242303498

OCS

Andere Sprachen

Filter